RPG Life Sciences' Q4 FY 2025-26 Quarterly Results

Result Summary

• RPG Life Sciences Ltd reported a 3.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a - of -.
• Its expenses for the quarter were up by 2.9% QoQ and - - YoY.
• The net profit increased 35.1% QoQ and - - YoY.
• The earnings per share (EPS) of RPG Life Sciences Ltd stood at 18.08 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

RPG Life Sciences Ltd is a company primarily engaged in the pharmaceutical industry, known for its involvement in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company's product portfolio typically includes formulations, active pharmaceutical ingredients (APIs), and biotechnology products. RPG Life Sciences operates both domestically within India and internationally, catering to various therapeutic segments. It is part of the larger RPG Group, a diversified conglomerate in India with interests spanning multiple sectors such as infrastructure, technology, and energy. While specific recent developments or strategic initiatives in the current fiscal year are not detailed, the company's ongoing operations are supported by its established manufacturing capabilities and research and development initiatives.

Revenue

For the fourth quarter of the fiscal year 2026 (Q4FY26), RPG Life Sciences Ltd reported a total income of ₹189.29 crores. This represents a quarter-over-quarter (QoQ) increase of 3.2% compared to ₹183.44 crores in the third quarter of fiscal year 2026 (Q3FY26). The data for the corresponding quarter of the previous fiscal year (Q4FY25) is not available, hence the year-over-year (YoY) comparison cannot be determined. The increase in total income on a QoQ basis suggests sustained revenue generation for the company during this period.

Profitability

The company's profitability metrics for Q4FY26 indicate a strong performance. The Profit Before Tax (PBT) was reported at ₹40.20 crores, marking a significant QoQ increase of 38.0% from ₹29.12 crores in Q3FY26. Following tax expenses of ₹10.30 crores in Q4FY26, the Profit After Tax (PAT) amounted to ₹29.90 crores, up by 35.1% QoQ from ₹22.13 crores in the previous quarter. Earnings Per Share (EPS) for the quarter stood at ₹18.08, also reflecting a 35.1% QoQ growth from ₹13.38 in Q3FY26. The tax expense increased by 47.4% QoQ, indicating higher taxable income during the quarter. The absence of data for Q4FY25 precludes YoY profitability analysis.

Operating Metrics

The operating metrics for RPG Life Sciences Ltd during Q4FY26 show an increase in both total income and expenses. Total expenses for the quarter were ₹150.19 crores, rising by 2.9% QoQ from ₹145.90 crores in Q3FY26. While the expenses grew, the increase in total income was sufficient to enhance overall profitability, as reflected in the notable rise in both PBT and PAT. The efficiency in managing operating costs relative to income growth is evident from the performance metrics provided for the quarter. Without information on other potential operating metrics such as inventory turnover or debt levels, the analysis is limited to these provided financial figures.